drugset / Trial / NCT07160738

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

NCT07160738

Phase 1 Completed 25 enrolled Pfizer
Non-randomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to see and learn the effect of multiple doses of a strong CYP3A4 inhibitor and a potent UGT2B7 inhibitor on the PK of PF-07220060.

Timeline

Start
2025-09-22
Primary completion
2025-11-24
Completion
2025-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Atirmociclib Small molecule Oral
Subject Itraconazole Small molecule Oral
Subject Probenecid Small molecule

Indications

No indication recorded.